From Candidate to Clinic
How Smart Startups De-Risk Their Molecules and Accelerate Clinical Entry
Date
Thursday, 25 June 2026
Time
5:00pm - 7:00pm
Location
Switzerland Innovation Park Basel Area Main Campus HQ
Hegenheimermattweg 167A, 4123 Allschwil, Switzerland
Why attend:
The Swiss biotech ecosystem excels at scientific discovery: how to best transition from a promising molecule to a clinical-stage asset? Startups need a fast, smooth and robust path to de-risk their programs before entering the clinic. This panel brings together an early drug development expert, a biotech founder, a life science consultant, and an ecosystem partner to explore the critical steps between lead selection and first-in-human studies.
The discussion will focus on how early technical and strategic decisions, from development planning and CMC strategy to outsourcing and partner selection, can accelerate timelines, reduce risk, and prevent rework. Attendees will gain practical insights into when it makes sense to build capabilities internally and when relying on experienced partners creates greater long-term value.
Agenda:
- 5.00pm: Registration / Finger Food Lunch / Networking
- 5.30pm: Welcome and Panel Introduction from Martina De Gennaro
- 5.40: Panel Discussion
- 6.10: Audience Q&A
- 6:30: Closing Remarks from Jeffry Grunkemeyer - 1:1s and Networking Opportunity
Panelists:
- CMC Expert for IND/BLA
- Technical & Proposal Senior Manager Lonza Integrated Biologics
- Biotech Startup Accelerator Expert
- Representative of a Swiss Biotech developing Biologics Therapeutics
Please complete the form below to register your interest.
Thank you for your interest. Once registered, you will receive a confirmation email if your participation is approved. To ensure a focused discussion and due to limited capacity, this event is reserved for biotech companies and organizations developing human therapeutics.
